From another board, "Nanoparticle Formulations"...
The Celsion (CLSN) news from May 22 clearly stated:
"...announced today that its proprietary patent application, "Method of Storing Nanoparticle Formulations," has now been granted in the four largest markets for liver cancer globally: China, Japan, South Korea and most recently Taiwan. Celsion holds an exclusive license agreement with Duke University for its temperature sensitive liposome technology which covers the ThermoDox® formulation. Celsion's newly issued patents pertain specifically to methods of storing stabilized, temperature-sensitive liposomal formulations..."
The key phrases being "now been granted" and "storing nanoparticle formulations"
Apparently no one has a clue how hard it is to store these things, and no one realizes that there are many biotech companies with nanoparticle formulations that need stable storage solutions.
These all become potential licensee's for Celsion's patented technology. Right after this news was released last week is when Celsion began this move up.
So, I guess someone on Wall Street figured it out, and is buying heavily.
Furthermore, remember that one of Celsion's breakthroughs was when they were able to get rid of the need for a Pharmacist to be there for every Thermodox treatment to mix two vials just prior to infusion.
They perfected a storage system and through the leadership of Robert Reed they were able to make commercial grade and size batches and store them in vials frozen, and proved the shelf life and stability and post-freezing efficacy of the single-vial Thermodox method.
If the patent was written well, it could cover ANY such future developments that want to store any drug-encapsulated nanoparticle (such as Capsutech's mechanical release product, or UCSD's nanoworm, or albumin-based gas particles, or any of Bracco's latest attempts at having anything of value in this sector, or others) and that could mean some nice licensing income.
